Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report

Grigsby PW: Vaginal cancer. Curr Treat Options Oncol. 3:125–130. 2002. View Article : Google Scholar

Creasman WT: Vaginal cancers. Curr Opin Obstet Gynecol. 17:71–76. 2005. View Article : Google Scholar

Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001. View Article : Google Scholar

Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT and Viens P: A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 108:42–46. 2008. View Article : Google Scholar

Tran PT, Su Z, Lee P, Lavori P, Husain A, Teng N and Kapp DS: Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol. 105:641–649. 2007. View Article : Google Scholar : PubMed/NCBI

Yeh AM, Marcus RB Jr, Amdur RJ, Morgan LS and Million RR: Patterns of failure in squamous cell carcinoma of the vagina treated with definitive radiotherapy alone: what is the appropriate treatment volume? Int J Cancer. 96(Suppl): 109–116. 2001.

Piperdi B and Perez-Soler R: Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs. 72(Suppl 1): 11–19. 2012. View Article : Google Scholar

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, et al: Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 102:1032–1037. 2011. View Article : Google Scholar

Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, et al: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, et al; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010. View Article : Google Scholar